๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Gastric (Stomach) Cancer
Clinical trial register · China

Gastric (Stomach) Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Tongling 3 Shanghai 2 Beijing 2 Zhengzhou 2 Hangzhou 1
Narrow the registerReset
Recruitment status
Phase
Site location
Tongling3 Shanghai2 Beijing2 Zhengzhou2 Hangzhou1
All 10 locations
Target enrolment
to

Gastric (Stomach) Cancer trials in China

13 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial
NCT06943794Gastric (Stomach) Cancer
Fudan University
Not applicable
4,824
Tongling
2026-03-30
Recruiting
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
NCT07371663Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer
Beijing Tide Pharmaceutical Co., Ltd
Phase 1/2
266
Beijing, Zhengzhou, Hangzhou
2025-12-03
Recruiting
Prospective Gastric Cancer Screening With Fecal Multi-target DNA Analysis
NCT06943807Gastric (Stomach) Cancer
Fudan University
Observational
15,000
Tongling
2025-07-01
Recruiting
An Observational Study for Gastric Cancer in Carriers of High Risk Helicobacter Pylori
NCT06896370Gastric (Stomach) Cancer, Helicobacter Infection
Fudan University
Observational
3,000
Tongling
2025-07-01
Recruiting
The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial
NCT07212933Gastric (Stomach) Cancer, Biological Therapy, Immunotherapy
Chinese PLA General Hospital
Phase 2
90
Beijing
2025-07-01
Recruiting
Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Gastric Cancer
NCT06979895Gastric (Stomach) Cancer
Xijing Hospital
Observational
150
Xi'an
2025-05-26
By invitation
Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07356466Gastric (Stomach) Cancer
Fujian Medical University
Phase EARLY_PHASE1
100
Fuzhou
2025-05-01
Not yet open
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
NCT06871527Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Fruquintinib, PD-1 Inhibitor
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 1/2
44
Guangzhou
2025-03-01
Active, closed
Fecal DNA Methylation and Helicobacter Pylori SNPs Tests for Gastric Cancer
NCT07312500Gastric (Stomach) Cancer
Fudan University
Observational
3,000
Shanghai
2025-01-01
Recruiting
XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
NCT06742411Gastric (Stomach) Cancer
West China Hospital
Phase 1/2
57
Chengdu
2024-12-31
Recruiting
Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
NCT07334431Gastric Adenocarcinoma, Gastric (Stomach) Cancer, GEJ Adenocarcinoma, HER2-positive Gastric Cancer
Henan Cancer Hospital
Phase 1/2
45
Zhengzhou
2024-02-22
Active, closed
A Study on the Impact of Intelligent Nutrition Management on Clinical Outcomes in Chemotherapy Patients With Gastrointestinal Malignancies
NCT06997302Gastric (Stomach) Cancer, Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital
Not applicable
150
Tianjin
2022-01-01
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/condition/gastric-stomach-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies listing the condition Gastric (Stomach) Cancer.

How many Gastric (Stomach) Cancer trials are recruiting in China?

7 of the 13 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 2 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Gastric (Stomach) Cancer), 13 studies
PhaseStudiesRecruitingShare
Observational4330.8%
Phase 1/24330.8%
Not applicable2015.4%
Phase 22115.4%
Phase EARLY_PHASE1107.7%

Most active sponsors

Lead sponsors with the most studies (Gastric (Stomach) Cancer)
Lead sponsorStudiesRecruiting
Fudan University52
Beijing Tide Pharmaceutical Co., Ltd11
Chinese PLA General Hospital11
Fujian Medical University10
Henan Cancer Hospital11
Sixth Affiliated Hospital, Sun Yat-sen University10
Tianjin Medical University Cancer Institute and Hospital10
West China Hospital11
Xijing Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.